Eli Lilly: targets raised for 2017.
(CercleFinance.com) - On unveiling its quarterly results, Eli Lilly has stated that it is now targeting FY 2017 adjusted (non-GAAP) EPS of between 4.
15 dollars and 4.25 dollars, against a previous target range of 4.10 dollars to 4.20 dollars.
The Indianapolis-based pharmaceuticals company also raised its target sales range to between 22.4 billion dollars and 22.7 billion dollars, while it previously expected annual revenues of between 22 billion and 22.5 billion dollars.
Over Q3, Eli Lilly reported adjusted EPS that was up 19% at 1.05 dollar, two cents above the consensus, on sales that were up 9% at nearly 5.7 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
15 dollars and 4.25 dollars, against a previous target range of 4.10 dollars to 4.20 dollars.
The Indianapolis-based pharmaceuticals company also raised its target sales range to between 22.4 billion dollars and 22.7 billion dollars, while it previously expected annual revenues of between 22 billion and 22.5 billion dollars.
Over Q3, Eli Lilly reported adjusted EPS that was up 19% at 1.05 dollar, two cents above the consensus, on sales that were up 9% at nearly 5.7 billion dollars.
Copyright (c) 2017 CercleFinance.com. All rights reserved.